To prohibit the obligation or expenditure of Department of Health and Human Services funds for the use of live dogs and live cats in biomedical research, to strengthen accountability for Federal research expenditures, and for other purposes.

On September 21, 2026, Representative Langworthy (R-NY-23) introduced HR10522, the 'Prohibition on the Use of Live Dogs and Cats in Biomedical Research Act' (title not provided, but the description is clear). The bill was referred to the House Committee on Energy and Commerce, the primary authorizing committee for the NIH. At this early stage (introduced, referred), the bill has no binding effect; it would require committee markup, floor votes in both chambers, and presidential action to become law. The bill's mechanism is a prohibition on HHS funds (including NIH grants) for research using live dogs and cats, coupled with strengthened accountability for federal research expenditures. This is a targeted restriction on a specific animal model class, not a broad funding cut. The direct consequence would be that NIH-funded institutions—universities, medical centers, and contract research organizations (CROs)—would need to shift away from canine/feline models toward alternatives (e.g., in vitro, computational, or other species). This could increase short-term compliance and transition costs but may accelerate the adoption of non-animal technologies. The bill does not authorize any new funding; it is a restriction on existing appropriations. Given the early stage and the absence of companion legislation or committee action, the probability of enactment in the 119th Congress is low but not negligible, especially if it gains cosponsors and committee attention. The market impact is currently minimal, but the bill is part of a broader legislative trend toward reducing animal testing, which could benefit companies developing alternative testing platforms.